Clone-by-Clone Therapy Guidance in Luminal Breast Cancer via Spatial Proteomics and Patient-Derived Tumoroid.
Combining spatial protein mapping with patient-derived cancer cells reveals actionable treatment targets hidden by standard genetic testing in breast cancer.
This study from the Salzet/Fournier group demonstrates the feasibility of integrating spatial mass spectrometry-based proteomics with patient-derived tumoroid systems to identify actionable clonal vulnerabilities in luminal breast cancer. The approach moves beyond bulk genomic profiling to address intratumoral heterogeneity—a key driver of treatment failure—by providing clone-specific proteomic maps that can guide personalized drug selection, representing an important advance for precision oncology workflows.
What the study was
- Study design
- original_research_exploratory
- Population
- Luminal breast cancer patients (pilot study)
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Mol Cell Proteomics
Why it surfaced
Novel intersection of spatial proteomics and patient-derived organoids for intraclonal precision oncology; addresses core limitation of current single-biopsy genomic approaches; Mol Cell Proteomics is high-impact specialty journal; methodology applicable across tumor types.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.